Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42083
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VERBEECK, Johan | - |
dc.contributor.author | De Backer, Mickael | - |
dc.contributor.author | VERWERFT, Jan | - |
dc.contributor.author | Salvaggio, Samuel | - |
dc.contributor.author | Valgimigli, Marco | - |
dc.contributor.author | VRANCKX, Pascal | - |
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | Brunner, Edgar | - |
dc.date.accessioned | 2024-01-10T08:31:31Z | - |
dc.date.available | 2024-01-10T08:31:31Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2024-01-09T08:17:35Z | - |
dc.identifier.citation | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 82 (13) , p. 1360 -1372 | - |
dc.identifier.uri | http://hdl.handle.net/1942/42083 | - |
dc.description.abstract | A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials. | - |
dc.description.sponsorship | The data supporting this study's findings on the simulation of the TAVR-UNLOAD trial are available upon request from the corresponding author at johan.verbeeck@uhasselt.be. The data that support the findings of this study on the MATRIX study are available upon request from Dr Marco Valgimigli at marco.valgimigli@cardiocentro.org. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.rights | 2023 by the American College of Cardiology Foundation. Published by Elsevier. | - |
dc.subject.other | absolute treatment effect | - |
dc.subject.other | biostatistics | - |
dc.subject.other | clinical trials | - |
dc.subject.other | composite endpoints | - |
dc.subject.other | endpoint determinations | - |
dc.subject.other | generalized pairwise comparisons | - |
dc.subject.other | net treatment benefit | - |
dc.subject.other | randomized controlled trials as topic | - |
dc.subject.other | relative treatment effect | - |
dc.subject.other | success odds | - |
dc.subject.other | survival analysis | - |
dc.subject.other | win ratio | - |
dc.title | Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1372 | - |
dc.identifier.issue | 13 | - |
dc.identifier.spage | 1360 | - |
dc.identifier.volume | 82 | - |
local.format.pages | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Verbeeck, J (corresponding author), Univ Hasselt, DSI, I BioStat, Agoralaan Gebouw D, B-3590 Hasselt, Belgium. | - |
dc.description.notes | johan.verbeeck@uhasselt.be | - |
local.publisher.place | STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1016/j.jacc.2023.06.047 | - |
dc.identifier.pmid | 37730293 | - |
dc.identifier.isi | 001124754500001 | - |
dc.contributor.orcid | Verwerft, Jan/0000-0003-2697-0825; Verbeeck, Johan/0000-0002-4923-1032 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Verbeeck, Johan; Buyse, Marc] Univ Hasselt, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Data Sci Inst, Hasselt, Belgium. | - |
local.description.affiliation | [De Backer, Mickael; Salvaggio, Samuel; Buyse, Marc] Int Drug Dev Inst IDDI, Louvain La Neuve, Belgium. | - |
local.description.affiliation | [Verwerft, Jan; Vranckx, Pascal] Jessa Hosp Hasselt, Hasselt Heart Ctr, Dept Cardiol & Crit Care Med, Hasselt, Belgium. | - |
local.description.affiliation | [Verwerft, Jan; Vranckx, Pascal] Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium. | - |
local.description.affiliation | [Valgimigli, Marco] Univ Lugano, Univ Svizzera Italiana, Cardioctr Inst, Ente Osped Cantonale, Lugano, Switzerland. | - |
local.description.affiliation | [Brunner, Edgar] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany. | - |
local.description.affiliation | [Verbeeck, Johan] Univ Hasselt, DSI, I BioStat, Agoralaan Gebouw D, B-3590 Hasselt, Belgium. | - |
local.uhasselt.international | yes | - |
item.fulltext | With Fulltext | - |
item.fullcitation | VERBEECK, Johan; De Backer, Mickael; VERWERFT, Jan; Salvaggio, Samuel; Valgimigli, Marco; VRANCKX, Pascal; BUYSE, Marc & Brunner, Edgar (2023) Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 82 (13) , p. 1360 -1372. | - |
item.contributor | VERBEECK, Johan | - |
item.contributor | De Backer, Mickael | - |
item.contributor | VERWERFT, Jan | - |
item.contributor | Salvaggio, Samuel | - |
item.contributor | Valgimigli, Marco | - |
item.contributor | VRANCKX, Pascal | - |
item.contributor | BUYSE, Marc | - |
item.contributor | Brunner, Edgar | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 0735-1097 | - |
crisitem.journal.eissn | 1558-3597 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
published version.pdf Restricted Access | Published version | 3.17 MB | Adobe PDF | View/Open Request a copy |
auteursversion.pdf | Peer-reviewed author version | 8.17 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.